A Phase 2 interventional study of GSK1278863 and GSK1278863 matching Placebo in Anaemia, sponsored by GlaxoSmithKline. Completed at 38 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 12th largest by enrollment, is one of 5 that started in 2016, is one of 10 in phase 2, and was the 13th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 14th largest by enrollment, is one of 6 that started in 2016, is one of 11 in phase 2, and was the 18th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor, currently being investigated as a treatment for anemia associated with chronic kidney disease. GSK1278863 has been given as a once daily regimen in clinical studies to date. However, physicians in countries that use a three-times weekly hemodialysis schedule prefer to give the anemia medicine at the same time as the dialysis session. This study will test how well GSK1278863 can maintain hemoglobin levels when given three-times weekly, for 29 days.
This study will describe the relationship between hemoglobin and GSK1278863 given three-times weekly. The data from this study will allow for conversion of once daily doses to three-times weekly doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTE: Those with or are eligible provided these exclusions are not met.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
Drug: GSK1278863
Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
Drug: GSK1278863
Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
Drug: GSK1278863
Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
Drug: GSK1278863
Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
Drug: GSK1278863 matching Placebo
GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
Change From Baseline in Hgb Levels at Day 29
Blood samples were collected from participants for measurement of Hgb values. Baseline is the average of Hgb measured at Week -2 and Day 1 visits. Change from Baseline at Day 29 was defined as post dose value at Day 29 minus Baseline value. The analysis was performed on intent-to-treat (ITT) Population which comprised of all randomized participants who received at least one dose of study treatment, had a Baseline and at least one corresponding on treatment assessment, including Hgb.
Time frame: Baseline and Day 29
Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO)
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on EPO. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at each given post-Baseline time point was calculated and the maximum change from Baseline was determined.
Time frame: Baseline and up to Day 29
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on VEGF. Day 1 values were considered as Baseline values. The percent change from Baseline at each given post-Baseline time point was calculated (expressed as geometric mean) and the maximum percent change from Baseline was determined.
Time frame: Baseline and up to Day 29
Percent Change From Baseline in Hepcidin at Day 29
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on hepcidin. Day 1 values were considered as Baseline values. The Percent change from Baseline at Day 29 post-Baseline time point was calculated and expressed as geometric mean and the maximum change from Baseline was determined.
Time frame: Baseline and Day 29
Change From Baseline in Hematocrit Levels
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on hematocrit. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.
Time frame: Baseline and Day 29
Change From Baseline in Red Blood Cell (RBC) Count
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on RBC count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.
Time frame: Baseline and Day 29
Change From Baseline in Reticulocyte Count
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on reticulocyte count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.
Time frame: Baseline and Day 29
Change From Baseline in Reticulocyte Hemoglobin (CHr)
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on CHr. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.
Time frame: Baseline and Day 29
Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) and AUC From Time Zero to Infinity (AUC[0-inf]) of Dapro
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for non-compartmental analysis (NCA). Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. The analysis was performed on PK Population, which comprised of all participants from whom a PK sample has been obtained and analyzed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29
Maximum Observed Concentration of Dapro in Plasma (Cmax)
Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated.
Time frame: Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29
Time to Reach Cmax (Tmax) and Apparent Terminal Half-life (t1/2) of Dapro
Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29
Number of Participants Who Discontinued Study Treatment
Reasons of study treatment discontinuation included adverse events (AEs), protocol deviation, participants reached protocol defined stopping criteria, physician decision and withdrawal by participants. Number of participants who discontinued study treatment are presented. Analysis was performed on Safety Population which comprised of all participants who received at least one dose of study treatment.
Time frame: Up to Day 43
Number of Participants With AEs and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.
Time frame: Up to Day 43
Sodium, Potassium, Glucose, Calcium, Phosphate Levels in Blood at Indicated Time Points
Serum sodium, potassium, glucose, corrected calcium and phosphate levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Albumin and Protein Levels in Blood at Indicated Tme Points
Serum albumin and protein levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (Alk. Phosph) Levels in Blood at Indicated Time Points
Serum ALT, AST and alk. phosph. levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Bilirubin, Direct Bilirubin and Indirect Bilirubin Levels in Blood at Indicated Time Points
Serum bilirubin, direct bilirubin and indirect bilirubin levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Change From Baseline in Sodium, Potassium, Glucose, Calcium and Phosphate Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including sodium, potassium, glucose, calcium and phosphate. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Change From Baseline in Albumin and Protein Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Change From Baseline in ALT, AST, Alk. Phosph. Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT, AST, Alk. phosph. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Change From Baseline in Bilirubin, Direct Bilirubin, Indirect Bilirubin Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including bilirubin, direct bilirubin and indirect bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Leukocytes, Neutrophils, Basophils, Eosinophils,Lymphocytes, Monocytes, Platelet Levels in Blood at Indicated Time Points
Serum leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelet levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Mean Corpuscular Hemoglobin (MCH) Levels in Blood at Indicated Time Points
Serum MCH levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Mean Corpuscular Hemoglobin Concentration (MCHC) Levels in Blood at Indicated Time Points
Serum MCHC levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Mean Corpuscular Volume (MCV) Levels in Blood at Indicated Time Points
Serum MCV levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Erythrocyte Distribution Width Levels in Blood at Indicated Time Points
Erythrocyte distribution width levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Day 43
Change From Baseline in MCH Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Change From Baseline in MCHC Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Change From Baseline in MCV Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Change From Baseline in Erythrocyte Distribution Width Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte distribution width. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Change From Baseline in Leukocytes, Neutrophils, Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes, platelets. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Day 43
Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Indicated Time Points
Single measurements of 12-lead ECG were obtained in supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT interval. Number of participants who had abnormal non clinically significant (NCS) and abnormal clinically significant (CS) ECG findings at Baseline (Week -4) and Day 29 are presented.
Time frame: Up to Day 29
Change From Baseline in ECG Mean Heart Rate
Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure HR. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value.
Time frame: Baseline and Day 29
Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval and QTcB
Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure PR interval, QRS duration, QT interval and QTcB. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and Day 29
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Pre-dialysis and Post-dialysis
Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair at specific time points. SBP and DBP were measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Up to Day 43
Pulse Rate Values at Pre-dialysis and Post-dialysis
Vital sign measurements including pulse rate values were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Up to Day 43
Weight Values at Post-dialysis
Vital sign measurements including weight values were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Up to Day 43
Change From Baseline in SBP and DBP Values at Pre-dialysis and Post-dialysis
Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair. SBP and DBP were measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as SBP and DBP value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Up to Day 43
Change From Baseline in Pulse Rate Value at Pre-dialysis and Post-dialysis
Vital sign measurements including pulse rate were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as pulse rate value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as pulse rate value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Up to Day 43
Change From Baseline in Weight at Post-dialysis
Vital sign measurements including weight were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Up to Day 43
Participants on Hemodialysis (HD) with anemia associated with chronic kidney disease (CKD) switching from Erythropoiesis-Stimulating Agent (ESA) treatment were recruited in this randomized, dose-ranging study. Participants with hemoglobin (Hgb) values between 9.0- 11.5 grams per deciliter (g/dL) were considered as eligible for recruitment.
| Milestone | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Started | 20 | 20 | 20 | 21 | 22 |
| Completed | 17 | 19 | 16 | 17 | 14 |
| Not completed | 3 | 1 | 4 | 4 | 8 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 | 2 |
| Withdrew: Other: reached stopping criteria | 0 | 1 | 2 | 3 | 4 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 | 0 |
Blood samples were collected from participants for measurement of Hgb values. Baseline is the average of Hgb measured at Week -2 and Day 1 visits. Change from Baseline at Day 29 was defined as post dose value at Day 29 minus Baseline value. The analysis was performed on intent-to-treat (ITT) Population which comprised of all randomized participants who received at least one dose of study treatment, had a Baseline and at least one corresponding on treatment assessment, including Hgb.
| g/dL | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hgb Levels at Day 29 | -0.61 ± 0.646 | -0.19 ± 1.750 | -0.13 ± 1.088 | 0.64 ± 1.453 | 0.55 ± 1.167 |
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on EPO. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at each given post-Baseline time point was calculated and the maximum change from Baseline was determined.
| International unit per liter (IU/L) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO) | 53.761 ± 132.6875 | 2.255 ± 84.8921 | 73.369 ± 95.9772 | 302.529 ± 469.8312 | 477.644 ± 388.9757 |
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on VEGF. Day 1 values were considered as Baseline values. The percent change from Baseline at each given post-Baseline time point was calculated (expressed as geometric mean) and the maximum percent change from Baseline was determined.
| Nanograms per liter (ng/L) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF) | 20.35 (-0.48 to 45.55) | 43.75 (16.44 to 77.45) | 32.16 (-4.77 to 83.41) | 53.34 (17.17 to 100.68) | 76.09 (34.89 to 129.88) |
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on hepcidin. Day 1 values were considered as Baseline values. The Percent change from Baseline at Day 29 post-Baseline time point was calculated and expressed as geometric mean and the maximum change from Baseline was determined.
| Micrograms per liter (µg/L) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Hepcidin at Day 29 | 27.81 (-12.68 to 87.08) | 35.37 (-1.13 to 85.34) | 3.83 (-17.85 to 31.24) | -36.74 (-49.91 to -20.12) | -36.09 (-57.24 to -4.48) |
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on hematocrit. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.
| Proportion of red blood cells in blood | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematocrit Levels | -0.0218 ± 0.02469 | -0.0127 ± 0.05396 | -0.0149 ± 0.05379 | 0.0150 ± 0.04511 | 0.0215 ± 0.03852 |
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on RBC count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.
| 10^12 cells/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Red Blood Cell (RBC) Count | -0.19 ± 0.263 | -0.12 ± 0.494 | -0.13 ± 0.500 | 0.12 ± 0.420 | 0.15 ± 0.342 |
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on reticulocyte count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.
| Percentage of reticulocyte | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count | -0.08 ± 0.848 | -0.11 ± 0.803 | -0.04 ± 0.581 | 0.43 ± 0.547 | 0.09 ± 0.695 |
Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on CHr. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.
| Picograms (pg) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Hemoglobin (CHr) | -0.15 ± 1.375 | 0.23 ± 1.335 | 0.26 ± 1.103 | 0.23 ± 1.040 | 0.59 ± 1.436 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for non-compartmental analysis (NCA). Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. The analysis was performed on PK Population, which comprised of all participants from whom a PK sample has been obtained and analyzed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| hour into nanograms/milliliter (h*ng/mL) | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|
| AUC (0-t); n= 19, 15, 16, 14 | 311.7 ± 91.4 | 416.7 ± 168.6 | 513.9 ± 396.1 | 1010 ± 92.3 |
| AUC (0-inf); n= 12, 9, 8, 11 | 348.2 ± 78.2 | 383.5 ± 142.7 | 1214 ± 41.6 | 1369 ± 59.3 |
Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated.
| ng/mL | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|
| Maximum Observed Concentration of Dapro in Plasma (Cmax) | 140.0 ± 104.0 | 141.4 ± 248.8 | 246.9 ± 311.5 | 387.3 ± 99.4 |
Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Hour | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|
| Tmax; n= 19, 15, 16, 14 | 2.456 ± 78.9 | 2.106 ± 82.1 | 2.297 ± 96.5 | 1.718 ± 58.0 |
| T1/2; n= 12, 9, 8, 11 | 2.086 ± 50.0 | 1.886 ± 62.3 | 1.418 ± 58.4 | 2.897 ± 38.7 |
Reasons of study treatment discontinuation included adverse events (AEs), protocol deviation, participants reached protocol defined stopping criteria, physician decision and withdrawal by participants. Number of participants who discontinued study treatment are presented. Analysis was performed on Safety Population which comprised of all participants who received at least one dose of study treatment.
| Participants | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| AEs | 0 | 0 | 1 | 0 | 1 |
| Protocol deviation | 1 | 0 | 0 | 1 | 2 |
| Participant reached stopping criteria | 0 | 1 | 2 | 3 | 4 |
| Physician decision | 1 | 0 | 0 | 0 | 0 |
| Withdrawal by subject | 1 | 0 | 1 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.
| Participants | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Any AE | 10 | 10 | 6 | 7 | 7 |
| Any SAE | 4 | 3 | 2 | 1 | 3 |
Serum sodium, potassium, glucose, corrected calcium and phosphate levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Millimoles per liter (mmol/L) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Sodium; Day 1; n= 18, 20, 20, 22, 22 | 138.8 ± 2.85 | 138.1 ± 2.31 | 138.7 ± 2.83 | 139.4 ± 2.38 | 138.4 ± 1.76 |
| Sodium; Day 15; n= 17, 20, 18, 22, 20 | 137.7 ± 3.16 | 137.5 ± 2.72 | 138.1 ± 1.60 | 138.0 ± 2.36 | 137.2 ± 1.74 |
| Sodium; Day 29; n= 17, 19, 18, 19, 17 | 137.8 ± 3.96 | 136.8 ± 2.70 | 137.9 ± 2.85 | 138.8 ± 2.74 | 137.1 ± 2.46 |
| Sodium; Day 43; n= 15, 20, 18, 21, 21 | 139.2 ± 2.88 | 138.1 ± 1.77 | 137.9 ± 2.37 | 138.8 ± 2.02 | 137.6 ± 1.88 |
| Potassium; Day 1; n= 18, 20, 20, 22, 22 | 4.68 ± 0.840 | 4.73 ± 0.768 | 4.64 ± 0.826 | 4.79 ± 0.514 | 4.83 ± 0.685 |
| Potassium; Day 15; n= 17, 20, 18, 22, 20 | 4.72 ± 0.763 | 4.77 ± 0.542 | 4.57 ± 0.635 | 4.82 ± 0.765 | 4.80 ± 0.791 |
| Potassium; Day 29; n= 17, 19, 18, 19, 17 | 4.78 ± 0.919 | 4.87 ± 0.751 | 4.57 ± 0.472 | 4.86 ± 0.619 | 4.96 ± 0.941 |
| Potassium; Day 43; n= 15, 20, 18, 21, 21 | 4.69 ± 0.951 | 4.68 ± 0.562 | 4.59 ± 0.657 | 4.76 ± 0.752 | 4.80 ± 0.946 |
| Glucose; Day 1; n= 18, 20, 20, 22, 22 | 6.66 ± 3.088 | 6.66 ± 2.716 | 6.41 ± 3.507 | 7.05 ± 2.491 | 8.95 ± 5.012 |
| Glucose; Day 15; n= 17, 20, 18, 22, 20 | 7.89 ± 3.425 | 7.16 ± 2.844 | 7.03 ± 3.236 | 7.26 ± 2.852 | 8.67 ± 4.198 |
| Glucose; Day 29; n= 17, 19, 18, 19, 17 | 8.21 ± 4.951 | 7.49 ± 3.949 | 7.21 ± 3.953 | 7.77 ± 4.621 | 8.75 ± 5.708 |
| Glucose; Day 43; n= 15, 20, 18, 21, 21 | 6.93 ± 3.126 | 6.72 ± 2.965 | 7.09 ± 3.533 | 6.27 ± 1.958 | 8.93 ± 4.280 |
| Calcium corrected; Day 1; n= 18, 20, 20, 22, 22 | 2.286 ± 0.2116 | 2.270 ± 0.1244 | 2.241 ± 0.1675 | 2.219 ± 0.1589 | 2.215 ± 0.1163 |
| Calcium corrected; Day 15; n= 17, 20, 18, 22, 20 | 2.261 ± 0.1698 | 2.219 ± 0.1252 | 2.213 ± 0.1723 | 2.188 ± 0.1360 | 2.203 ± 0.1111 |
| Calcium corrected; Day 29; n= 17, 19, 18, 19, 17 | 2.205 ± 0.1431 | 2.248 ± 0.1352 | 2.244 ± 0.1577 | 2.198 ± 0.1343 | 2.225 ± 0.1810 |
| Calcium corrected; Day 43; n= 15, 20, 18, 21, 21 | 2.251 ± 0.1582 | 2.235 ± 0.1593 | 2.271 ± 0.1823 | 2.201 ± 0.1206 | 2.256 ± 0.1473 |
| Phosphate; Day 1; n= 18, 20, 20, 22, 22 | 1.608 ± 0.5143 | 1.528 ± 0.5557 | 1.498 ± 0.5265 | 1.318 ± 0.3647 | 1.566 ± 0.4269 |
| Phosphate; Day 15; n= 17, 20, 18, 22, 20 | 1.621 ± 0.4221 | 1.710 ± 0.3912 | 1.642 ± 0.5021 | 1.348 ± 0.3138 | 1.645 ± 0.4785 |
| Phosphate; Day 29; n= 17, 19, 18, 19, 17 | 1.709 ± 0.5872 | 1.592 ± 0.4121 | 1.644 ± 0.5322 | 1.453 ± 0.4489 | 1.550 ± 0.3575 |
| Phosphate; Day 43; n= 15, 20, 18, 21, 21 | 1.550 ± 0.5828 | 1.460 ± 0.4550 | 1.472 ± 0.4240 | 1.412 ± 0.4441 | 1.398 ± 0.4718 |
Serum albumin and protein levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| grams per liter (g/L) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Albumin; Day 1; n= 18, 20, 20, 22, 22 | 37.6 ± 2.89 | 38.6 ± 2.46 | 38.7 ± 3.84 | 38.8 ± 2.22 | 38.1 ± 3.52 |
| Albumin; Day 15; n= 17, 20, 18, 22, 20 | 38.1 ± 2.68 | 38.1 ± 2.65 | 38.4 ± 3.42 | 38.4 ± 2.52 | 37.2 ± 3.01 |
| Albumin; Day 29; n= 17, 19, 18, 19, 17 | 36.5 ± 3.22 | 37.2 ± 3.26 | 37.6 ± 3.62 | 37.4 ± 2.17 | 36.9 ± 4.15 |
| Albumin; Day 43; n= 15, 20, 18, 21, 21 | 37.1 ± 2.85 | 38.1 ± 3.02 | 37.9 ± 3.95 | 39.0 ± 3.11 | 37.5 ± 2.86 |
| Protein; Day 1; n= 18, 20 ,20, 22, 22 | 67.3 ± 4.90 | 66.9 ± 5.42 | 67.4 ± 4.89 | 66.4 ± 5.16 | 65.7 ± 4.65 |
| Protein; Day 15; n= 17, 20, 18, 22, 20 | 68.1 ± 4.87 | 66.5 ± 4.88 | 67.3 ± 4.28 | 65.6 ± 5.13 | 64.3 ± 4.70 |
| Protein; Day 29; n= 17, 19, 18, 19, 17 | 66.1 ± 4.52 | 65.7 ± 4.75 | 66.0 ± 4.51 | 65.5 ± 6.50 | 65.3 ± 5.30 |
| Protein; Day 43; n= 15, 20, 18, 21, 21 | 67.2 ± 4.25 | 67.4 ± 5.14 | 66.8 ± 4.02 | 66.7 ± 7.70 | 66.6 ± 6.34 |
Serum ALT, AST and alk. phosph. levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| IU/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| ALT; Day 1; n= 18, 20, 20, 22, 22 | 12.6 ± 9.36 | 13.4 ± 7.51 | 14.6 ± 11.39 | 10.7 ± 5.75 | 11.5 ± 5.94 |
| ALT; Day 15; n= 17, 20, 18, 22, 20 | 16.5 ± 13.80 | 13.9 ± 10.58 | 12.4 ± 7.87 | 11.9 ± 6.58 | 8.4 ± 2.11 |
| ALT; Day 29; n= 17, 19, 18, 19, 17 | 24.4 ± 32.34 | 12.8 ± 6.43 | 12.2 ± 6.40 | 10.9 ± 5.67 | 8.6 ± 3.12 |
| ALT; Day 43; n= 15, 20, 18, 21, 21 | 14.3 ± 8.55 | 13.8 ± 8.03 | 12.8 ± 6.89 | 13.1 ± 5.19 | 11.2 ± 5.57 |
| AST; Day 1; n= 18, 20, 20, 22, 22 | 14.9 ± 5.58 | 14.2 ± 5.19 | 17.2 ± 12.31 | 14.4 ± 5.85 | 13.6 ± 3.63 |
| AST; Day 15; n= 17, 20, 18, 22, 20 | 17.1 ± 7.30 | 14.3 ± 5.67 | 15.0 ± 7.72 | 15.4 ± 6.33 | 12.4 ± 2.89 |
| AST; Day 29; n= 17, 19, 18, 19, 17 | 26.8 ± 30.04 | 13.8 ± 5.01 | 16.0 ± 8.44 | 15.0 ± 6.35 | 13.5 ± 3.12 |
| AST; Day 43; n= 15, 20, 18, 21, 21 | 15.9 ± 6.65 | 14.9 ± 6.07 | 17.2 ± 11.40 | 15.7 ± 6.31 | 14.3 ± 4.76 |
| Alk. phosph; Day 1; n= 18, 20, 20, 22, 22 | 97.0 ± 33.07 | 112.3 ± 74.61 | 106.8 ± 84.85 | 99.4 ± 47.26 | 115.4 ± 72.35 |
| Alk. phosph; Day 15; n= 17, 20, 18, 22,20 | 102.4 ± 34.70 | 115.4 ± 73.37 | 114.5 ± 82.29 | 101.5 ± 56.44 | 110.0 ± 62.65 |
| Alk. phosph.; Day 29; n= 17, 19, 18, 19,17 | 94.1 ± 35.07 | 120.2 ± 81.15 | 109.2 ± 83.14 | 93.5 ± 42.92 | 120.4 ± 67.51 |
| Alk. phosph.; Day 43; n= 15, 20, 18, 21,21 | 96.5 ± 34.12 | 117.6 ± 76.61 | 113.8 ± 78.69 | 116.2 ± 96.02 | 108.6 ± 50.49 |
Serum bilirubin, direct bilirubin and indirect bilirubin levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Micromoles per liter (µmol/L) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Bilirubin; Day 1; n= 18, 20, 20, 22, 22 | 6.6 ± 1.65 | 7.8 ± 3.11 | 6.6 ± 1.31 | 6.5 ± 1.10 | 7.2 ± 2.44 |
| Bilirubin; Day 15; n= 17, 20, 18, 22, 20 | 6.7 ± 3.08 | 7.1 ± 2.29 | 7.2 ± 2.67 | 6.5 ± 1.10 | 7.8 ± 2.24 |
| Bilirubin; Day 29; n= 17, 19, 18, 19, 17 | 6.8 ± 2.24 | 6.9 ± 1.93 | 7.6 ± 2.12 | 6.5 ± 1.47 | 7.8 ± 2.44 |
| Bilirubin; Day 43; n= 15, 20 ,18, 21, 21 | 6.0 ± 1.07 | 7.0 ± 2.38 | 7.2 ± 2.07 | 6.5 ± 1.25 | 7.5 ± 2.44 |
| Direct bilirubin; Day 1; n= 18, 20, 20, 22, 22 | 1.8 ± 1.17 | 1.9 ± 0.79 | 2.0 ± 1.12 | 1.9 ± 0.75 | 2.4 ± 1.33 |
| Direct bilirubin; Day 15; n= 17, 20, 18, 22, 20 | 1.5 ± 1.66 | 2.2 ± 0.62 | 2.4 ± 1.29 | 1.8 ± 0.85 | 2.6 ± 1.14 |
| Direct bilirubin; Day 29; n= 17, 19, 18, 19,17 | 2.5 ± 2.29 | 1.6 ± 1.07 | 2.7 ± 0.97 | 1.8 ± 0.63 | 2.4 ± 1.46 |
| Direct bilirubin; Day 43; n= 15, 20, 18, 21,21 | 1.3 ± 1.23 | 1.9 ± 0.45 | 2.3 ± 0.77 | 1.7 ± 0.72 | 2.3 ± 1.31 |
| Indirect bilirubin; Day 1; n= 18, 20, 20, 22, 22 | 4.8 ± 1.22 | 5.9 ± 2.94 | 4.6 ± 0.94 | 4.6 ± 1.14 | 4.8 ± 1.92 |
| Indirect bilirubin; Day 15; n= 17, 20, 18, 22, 20 | 5.2 ± 2.01 | 4.9 ± 2.10 | 4.8 ± 1.83 | 4.7 ± 0.98 | 5.2 ± 1.77 |
| Indirect bilirubin; Day 29; n= 17, 19, 18, 19, 17 | 4.4 ± 2.03 | 5.4 ± 1.64 | 4.9 ± 1.57 | 4.7 ± 1.52 | 5.4 ± 1.70 |
| Indirect bilirubin; Day 43; n= 15, 20, 18, 21, 21 | 4.7 ± 0.98 | 5.1 ± 2.38 | 4.9 ± 1.41 | 4.8 ± 1.48 | 5.2 ± 1.73 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including sodium, potassium, glucose, calcium and phosphate. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Mmol/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Sodium; Day 15; n= 17, 20, 18, 22, 20 | -0.9 ± 2.73 | -0.6 ± 2.62 | -0.5 ± 2.64 | -1.4 ± 2.06 | -1.0 ± 2.13 |
| Sodium; Day 29; n= 17, 19, 18, 19, 17 | -1.1 ± 2.26 | -1.2 ± 3.08 | -0.9 ± 2.26 | -0.5 ± 2.82 | -1.2 ± 2.70 |
| Sodium; Day 43; n= 15, 20, 18, 21, 21 | 0.7 ± 2.06 | 0.1 ± 2.35 | -0.6 ± 2.28 | -0.5 ± 2.60 | -0.6 ± 2.23 |
| Potassium; Day 15; n= 17, 20, 18, 22, 20 | 0.04 ± 0.462 | 0.05 ± 0.526 | -0.09 ± 1.099 | 0.03 ± 0.944 | -0.08 ± 0.635 |
| Potassium; Day 29; n= 17, 19, 18, 19, 17 | 0.20 ± 0.744 | 0.05 ± 0.660 | -0.14 ± 0.651 | 0.02 ± 0.640 | 0.11 ± 0.673 |
| Potassium; Day 43; n= 15, 20, 18, 21, 21 | 0.04 ± 0.565 | -0.05 ± 0.674 | -0.06 ± 1.004 | -0.06 ± 0.579 | -0.02 ± 0.932 |
| Glucose; Day 15; n= 17, 20, 18, 22, 20 | 1.14 ± 3.339 | 0.51 ± 2.959 | 0.45 ± 1.740 | 0.21 ± 1.620 | -0.03 ± 2.364 |
| Glucose; Day 29; n= 17, 19, 18, 19, 17 | 1.48 ± 3.771 | 0.70 ± 3.756 | 0.73 ± 1.135 | 0.61 ± 4.188 | -0.36 ± 3.786 |
| Glucose; Day 43; n= 15, 20, 18, 21, 21 | 0.23 ± 1.335 | 0.06 ± 3.072 | 0.52 ± 1.383 | -0.81 ± 2.516 | -0.12 ± 3.619 |
| Calcium; Day 15; n= 17, 20, 18, 22, 20 | -0.011 ± 0.1227 | -0.051 ± 0.1354 | -0.026 ± 0.1439 | -0.031 ± 0.0956 | -0.010 ± 0.0912 |
| Calcium; Day 29; n= 17, 19, 18, 19, 17 | -0.054 ± 0.1486 | -0.025 ± 0.1129 | -0.009 ± 0.1556 | -0.012 ± 0.0939 | 0.001 ± 0.1019 |
| Calcium; Day 43; n= 15, 20, 18, 21, 21 | -0.015 ± 0.1576 | -0.035 ± 0.1261 | 0.018 ± 0.1852 | 0.001 ± 0.0742 | 0.033 ± 0.1489 |
| Phosphate; Day 15; n= 17, 20, 18, 22, 20 | -0.091 ± 0.4051 | 0.183 ± 0.5184 | 0.111 ± 0.5715 | 0.030 ± 0.3268 | 0.095 ± 0.3367 |
| Phosphate; Day 29; n= 17, 19, 18, 19, 17 | 0.091 ± 0.3882 | 0.011 ± 0.4932 | 0.069 ± 0.4950 | 0.129 ± 0.2740 | -0.026 ± 0.3653 |
| Phosphate; Day 43; n= 15, 20, 18, 21, 21 | -0.067 ± 0.4337 | -0.068 ± 0.5324 | -0.053 ± 0.5400 | 0.102 ± 0.3433 | -0.117 ± 0.5117 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| g/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Albumin; Day 15; n= 17, 20, 18, 22, 20 | 0.8 ± 1.60 | -0.5 ± 1.64 | 0.2 ± 2.24 | -0.5 ± 1.44 | -1.0 ± 2.34 |
| Albumin; Day 29; n= 17, 19, 18, 19, 17 | -0.5 ± 2.24 | -1.3 ± 2.03 | -0.7 ± 2.00 | -1.3 ± 1.85 | -0.9 ± 1.76 |
| Albumin; Day 43; n= 15, 20, 18, 21, 21 | 0.1 ± 2.00 | -0.6 ± 2.14 | -0.7 ± 2.22 | 0.1 ± 3.85 | -0.3 ± 1.74 |
| Protein; Day 15; n= 17, 20, 18, 22, 20 | 0.8 ± 2.97 | -0.4 ± 3.25 | 0.3 ± 3.65 | -0.7 ± 2.35 | -1.5 ± 3.03 |
| Protein; Day 29; n= 17, 19, 18, 19, 17 | -1.1 ± 4.26 | -0.8 ± 3.82 | -1.2 ± 2.90 | -1.0 ± 3.28 | 0.1 ± 2.56 |
| Protein; Day 43; n= 15, 20, 18, 21, 21 | -0.1 ± 4.19 | 0.6 ± 4.38 | -0.9 ± 3.17 | 0.3 ± 4.84 | 1.2 ± 3.95 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT, AST, Alk. phosph. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| IU/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| ALT; Day 15; n= 17, 20, 18, 22, 20 | 3.6 ± 9.59 | 0.5 ± 5.65 | -3.1 ± 5.53 | 1.1 ± 4.79 | -3.4 ± 5.52 |
| ALT; Day 29; n= 17, 19, 18, 19, 17 | 11.8 ± 32.39 | -0.9 ± 4.65 | -3.4 ± 9.83 | -0.2 ± 3.87 | -3.6 ± 4.72 |
| ALT; Day 43; n= 15, 20, 18, 21, 21 | 0.9 ± 4.32 | 0.4 ± 5.29 | -2.5 ± 8.97 | 2.2 ± 4.08 | -0.4 ± 3.69 |
| AST; Day 15; n= 17, 20, 18, 22, 20 | 2.3 ± 5.70 | 0.1 ± 2.45 | -2.7 ± 6.29 | 1.0 ± 5.26 | -1.6 ± 3.32 |
| AST; Day 29; n= 17, 19, 18, 19, 17 | 11.5 ± 30.64 | -0.3 ± 3.30 | -1.8 ± 5.60 | 0.9 ± 3.60 | -0.3 ± 3.67 |
| AST; Day 43; n= 15, 20, 18, 21, 21 | 0.6 ± 3.94 | 0.7 ± 2.49 | -0.6 ± 7.99 | 1.5 ± 3.71 | 0.7 ± 3.41 |
| Alk.phosph.; Day 15; n= 17, 20, 18, 22, 20 | 3.2 ± 10.28 | 3.2 ± 16.13 | 2.7 ± 29.73 | 2.1 ± 17.23 | -4.7 ± 18.90 |
| Alk.phosph.; Day 29; n= 17, 19, 18, 19, 17 | -0.4 ± 19.31 | 5.1 ± 19.09 | -0.9 ± 30.13 | 0.9 ± 13.47 | -1.2 ± 28.60 |
| Alk.phosph.; Day 43; n= 15, 20, 18, 21, 21 | -1.5 ± 17.01 | 5.4 ± 21.34 | 2.7 ± 31.96 | 18.0 ± 66.44 | -8.4 ± 56.06 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including bilirubin, direct bilirubin and indirect bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| µmol/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Bilirubin; Day 15; n= 17, 20, 18, 22, 20 | 0.2 ± 1.56 | -0.7 ± 1.49 | 0.8 ± 2.07 | 0.0 ± 1.38 | 0.5 ± 1.93 |
| Bilirubin; Day 29; n= 17, 19, 18, 19, 17 | 0.2 ± 0.97 | -0.3 ± 1.20 | 1.0 ± 1.41 | 0.1 ± 1.56 | 0.2 ± 0.97 |
| Bilirubin; Day 43; n= 15, 20, 18, 21, 21 | -0.1 ± 0.52 | -0.8 ± 1.51 | 0.6 ± 2.04 | 0.1 ± 1.34 | 0.4 ± 1.36 |
| Direct bilirubin; Day 15; n= 17, 20, 18, 22, 20 | -0.1 ± 1.11 | 0.3 ± 0.73 | 0.6 ± 0.92 | -0.1 ± 0.97 | 0.2 ± 1.11 |
| Direct bilirubin; Day 29; n= 17, 19, 18, 19, 17 | 0.7 ± 1.86 | -0.3 ± 1.00 | 0.7 ± 0.97 | -0.1 ± 1.05 | -0.1 ± 1.50 |
| Direct bilirubin; Day 43; n= 15, 20, 18, 21, 21 | -0.1 ± 1.19 | 0.0 ± 0.92 | 0.3 ± 1.03 | -0.2 ± 1.08 | -0.1 ± 1.34 |
| Indirect bilirubin; Day 15; n= 17, 20, 18, 22, 20 | 0.4 ± 1.46 | -1.0 ± 1.38 | 0.2 ± 1.80 | 0.1 ± 1.44 | 0.3 ± 1.75 |
| Indirect bilirubin; Day 29; n= 17, 19, 18, 19, 17 | -0.5 ± 1.66 | 0.0 ± 1.15 | 0.3 ± 1.71 | 0.2 ± 1.62 | 0.4 ± 1.46 |
| Indirect bilirubin; Day 43; n= 15, 20, 18, 21, 21 | 0.0 ± 1.07 | -0.8 ± 1.64 | 0.2 ± 1.66 | 0.3 ± 1.82 | 0.5 ± 1.40 |
Serum leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelet levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| 10^12 cells/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Leukocytes; Day 1; n= 18, 19, 19, 20, 21 | 6.28 ± 1.750 | 6.07 ± 1.601 | 5.88 ± 1.510 | 6.44 ± 1.595 | 5.90 ± 1.825 |
| Leukocytes; Day 15; n= 17, 19, 17, 21, 21 | 7.01 ± 2.140 | 5.85 ± 1.720 | 6.21 ± 1.918 | 6.52 ± 1.427 | 5.87 ± 1.961 |
| Leukocytes; Day 29; n= 16, 19, 17, 18, 17 | 6.66 ± 1.707 | 6.59 ± 1.890 | 5.88 ± 1.685 | 6.33 ± 1.820 | 6.11 ± 2.574 |
| Leukocytes; Day 43; n= 16, 20, 19, 20, 19 | 7.05 ± 2.006 | 7.25 ± 2.520 | 6.00 ± 1.694 | 6.77 ± 2.547 | 6.42 ± 2.010 |
| Neutrophils; Day 1; n= 18, 19, 19, 20, 21 | 4.030 ± 1.6128 | 4.097 ± 1.5763 | 3.522 ± 1.3492 | 3.954 ± 1.4097 | 3.785 ± 1.5024 |
| Neutrophils; Day 15; n= 17, 19, 17, 21, 21 | 4.666 ± 1.8113 | 3.887 ± 1.5659 | 3.707 ± 1.6592 | 4.346 ± 1.2240 | 4.129 ± 1.6604 |
| Neutrophils; Day 29; n= 16, 18, 17, 17, 15 | 4.123 ± 1.2229 | 4.591 ± 1.9586 | 3.522 ± 1.4546 | 3.978 ± 1.7026 | 4.224 ± 2.2017 |
| Neutrophils; Day 43; n= 16, 20, 19, 19, 19 | 4.687 ± 1.8919 | 5.049 ± 2.3848 | 3.545 ± 1.4027 | 4.477 ± 2.2480 | 4.343 ± 1.6235 |
| Basophils; Day 1; n= 18, 19, 19, 20, 21 | 0.018 ± 0.0131 | 0.016 ± 0.0134 | 0.025 ± 0.0174 | 0.028 ± 0.0204 | 0.017 ± 0.0142 |
| Basophils; Day 15; n= 17, 19, 17, 21, 21 | 0.027 ± 0.0214 | 0.026 ± 0.0161 | 0.022 ± 0.0139 | 0.025 ± 0.0325 | 0.024 ± 0.0140 |
| Basophils; Day 29; n= 16, 18, 17, 17, 15 | 0.035 ± 0.0462 | 0.021 ± 0.0128 | 0.021 ± 0.0150 | 0.024 ± 0.0111 | 0.027 ± 0.0315 |
| Basophils; Day 43; n= 16, 20, 19, 19, 19 | 0.028 ± 0.0217 | 0.018 ± 0.0136 | 0.020 ± 0.0183 | 0.025 ± 0.0204 | 0.024 ± 0.0130 |
| Eosinophils; Day 1; n= 18, 19, 19, 20, 21 | 0.189 ± 0.1946 | 0.174 ± 0.1593 | 0.184 ± 0.1696 | 0.196 ± 0.2310 | 0.240 ± 0.2115 |
| Eosinophils; Day 15; n= 17, 19, 17, 21, 21 | 0.161 ± 0.1245 | 0.166 ± 0.1804 | 0.192 ± 0.2355 | 0.187 ± 0.2186 | 0.186 ± 0.1914 |
| Eosinophils; Day 29; n= 16, 18, 17, 17, 15 | 0.176 ± 0.1917 | 0.149 ± 0.0950 | 0.145 ± 0.1136 | 0.237 ± 0.2785 | 0.185 ± 0.0798 |
| Eosinophils; Day 43; n= 16, 20, 19, 19, 19 | 0.216 ± 0.2458 | 0.210 ± 0.1969 | 0.232 ± 0.2727 | 0.243 ± 0.2670 | 0.217 ± 0.1899 |
| Lymphocytes; Day 1; n= 18, 19, 19, 20, 21 | 1.631 ± 0.4264 | 1.393 ± 0.4587 | 1.739 ± 0.6964 | 1.747 ± 0.7325 | 1.442 ± 0.4998 |
| Lymphocytes; Day 15; n= 17, 19, 17, 21, 21 | 1.735 ± 0.6699 | 1.416 ± 0.5670 | 1.842 ± 0.7381 | 1.526 ± 0.6697 | 1.206 ± 0.4609 |
| Lymphocytes; Day 29; n= 16, 18, 17, 17, 15 | 1.870 ± 0.7427 | 1.427 ± 0.4187 | 1.775 ± 0.6767 | 1.612 ± 0.5775 | 1.181 ± 0.3418 |
| Lymphocytes; Day 43; n= 16, 20, 19, 19, 19 | 1.648 ± 0.5294 | 1.509 ± 0.4386 | 1.736 ± 0.3916 | 1.721 ± 0.6644 | 1.399 ± 0.5562 |
| Monocytes; Day 1; n= 18, 19, 20, 20, 21 | 0.401 ± 0.1511 | 0.396 ± 0.1591 | 0.435 ± 0.2703 | 0.518 ± 0.2077 | 0.421 ± 0.1722 |
| Monocytes; Day 15; n= 17, 19, 17, 21, 21 | 0.420 ± 0.2243 | 0.352 ± 0.1457 | 0.436 ± 0.2402 | 0.446 ± 0.2085 | 0.384 ± 0.2160 |
| Monocytes; Day 29; n= 16, 18, 17, 17, 15 | 0.444 ± 0.2076 | 0.457 ± 0.1503 | 0.403 ± 0.1385 | 0.600 ± 0.3465 | 0.426 ± 0.2628 |
| Monocytes; Day 43; n= 16, 20, 19, 19, 19 | 0.461 ± 0.1878 | 0.459 ± 0.1916 | 0.461 ± 0.2614 | 0.513 ± 0.2739 | 0.429 ± 0.2047 |
| Platelet; Day 1; n= 16, 19, 20, 19, 21 | 219.0 ± 65.04 | 189.9 ± 36.70 | 198.0 ± 71.03 | 196.0 ± 61.12 | 192.3 ± 70.85 |
| Platelet; Day 15; n= 17, 18, 17, 20, 21 | 205.4 ± 63.00 | 175.4 ± 44.08 | 198.5 ± 73.65 | 194.8 ± 49.08 | 181.5 ± 66.59 |
| Platelet; Day 29; n= 16, 19, 17, 17, 17 | 198.1 ± 76.39 | 174.7 ± 52.50 | 187.5 ± 62.66 | 198.9 ± 55.07 | 194.8 ± 81.57 |
| Platelet; Day 43; n= 15, 20, 19, 21, 20 | 220.8 ± 61.57 | 195.8 ± 68.33 | 188.6 ± 69.28 | 194.1 ± 50.35 | 170.0 ± 44.61 |
Serum MCH levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Pg | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 1; n= 18, 19, 20, 20, 21 | 31.19 ± 2.538 | 30.95 ± 1.889 | 30.19 ± 2.145 | 30.70 ± 1.781 | 31.46 ± 1.942 |
| Day 15; n= 17, 19, 17, 21, 21 | 30.83 ± 2.100 | 2.100 ± 1.866 | 30.74 ± 1.476 | 30.85 ± 1.619 | 31.70 ± 2.315 |
| Day 29; n= 16, 19, 17, 18, 17 | 30.97 ± 2.290 | 31.60 ± 2.194 | 30.56 ± 2.236 | 31.16 ± 1.729 | 31.68 ± 2.224 |
| Day 43; n= 16, 20, 19, 21, 20 | 30.86 ± 1.992 | 31.04 ± 1.870 | 30.49 ± 2.155 | 30.67 ± 1.846 | 31.84 ± 2.143 |
Serum MCHC levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| g/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 1; n= 18, 19, 20, 20, 21 | 322.9 ± 13.39 | 321.7 ± 12.61 | 319.5 ± 15.36 | 321.5 ± 12.91 | 327.6 ± 12.65 |
| Day 15; n= 17, 19, 17, 21, 21 | 321.5 ± 11.22 | 324.0 ± 7.79 | 324.8 ± 8.35 | 318.3 ± 12.06 | 322.7 ± 14.75 |
| Day 29; n= 16, 19, 17, 18, 17 | 323.3 ± 14.90 | 329.6 ± 12.61 | 325.4 ± 10.25 | 323.6 ± 8.61 | 323.9 ± 11.73 |
| Day 43; n= 16, 20, 19, 21, 20 | 321.9 ± 13.22 | 325.2 ± 11.98 | 325.5 ± 11.23 | 321.0 ± 11.00 | 327.0 ± 10.66 |
Serum MCV levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Femtoliter (fL) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 1; n= 18, 19, 20, 20, 21 | 96.7 ± 5.94 | 96.4 ± 5.68 | 94.7 ± 5.28 | 95.7 ± 4.91 | 96.1 ± 5.61 |
| Day 15; n= 17, 19, 17, 21, 21 | 95.9 ± 6.02 | 95.8 ± 6.27 | 94.8 ± 4.53 | 97.0 ± 6.41 | 98.3 ± 5.57 |
| Day 29; n= 16, 19, 17, 18, 17 | 95.8 ± 5.83 | 95.9 ± 6.05 | 94.1 ± 5.94 | 96.3 ± 4.76 | 97.8 ± 4.96 |
| Day 43; n= 16, 20, 19, 21, 20 | 96.1 ± 5.91 | 95.4 ± 5.08 | 93.7 ± 6.09 | 95.6 ± 5.27 | 97.5 ± 5.98 |
Erythrocyte distribution width levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Percentage of width | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 1; n= 18, 19, 20, 20, 21 | 15.13 ± 2.607 | 16.40 ± 2.082 | 15.41 ± 1.627 | 15.81 ± 2.504 | 15.68 ± 1.725 |
| Day 15; n= 17, 19, 17, 21, 21 | 15.05 ± 2.088 | 15.77 ± 1.569 | 15.26 ± 1.197 | 16.30 ± 2.331 | 16.74 ± 1.912 |
| Day 29; n= 16, 19, 17, 18, 17 | 15.15 ± 2.530 | 15.69 ± 1.750 | 15.36 ± 1.287 | 15.76 ± 1.253 | 16.23 ± 1.668 |
| Day 43; n= 16, 20, 19, 21, 20 | 15.53 ± 2.866 | 15.53 ± 2.018 | 14.95 ± 1.269 | 15.61 ± 1.297 | 15.48 ± 1.389 |
Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Pg | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 15; n= 17, 19, 17, 21, 21 | 0.16 ± 0.602 | 0.19 ± 0.817 | 0.27 ± 0.685 | 0.16 ± 0.520 | 0.25 ± 0.870 |
| Day 29; n= 16, 19, 17, 18, 17 | 0.16 ± 0.982 | 0.58 ± 1.185 | 0.42 ± 0.824 | 0.41 ± 0.744 | 0.15 ± 0.987 |
| Day 43; n= 16, 20, 19, 21, 20 | 0.11 ± 0.981 | 0.13 ± 0.948 | 0.34 ± 0.993 | 0.11 ± 0.842 | 0.29 ± 0.809 |
Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| g/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 15; n= 17, 19, 17, 21, 21 | 2.6 ± 11.09 | 3.0 ± 14.21 | 3.5 ± 10.87 | -3.2 ± 11.48 | -5.0 ± 12.92 |
| Day 29; n= 16, 19, 17, 18, 17 | 5.6 ± 12.81 | 7.3 ± 16.92 | 7.6 ± 8.27 | 0.8 ± 10.04 | -4.4 ± 12.30 |
| Day 43; n= 16, 20, 19, 21, 20 | 3.9 ± 15.92 | 3.0 ± 16.53 | 6.0 ± 11.44 | -1.0 ± 12.12 | -0.3 ± 9.14 |
Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| fL | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 15; n= 17, 19, 17, 21, 21 | -0.4 ± 2.98 | -0.2 ± 3.39 | -0.3 ± 2.57 | 1.3 ± 3.15 | 2.2 ± 3.21 |
| Day 29; n= 16, 19, 17, 18, 17 | -1.4 ± 3.24 | -0.5 ± 2.86 | -0.9 ± 2.36 | 0.9 ± 2.54 | 1.6 ± 2.40 |
| Day 43; n= 16, 20, 19, 21, 20 | -0.8 ± 3.15 | -0.7 ± 3.37 | -0.8 ± 3.28 | 0.6 ± 3.06 | 0.9 ± 2.10 |
Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte distribution width. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage of width | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 15; n= 17, 19, 17, 21, 21 | -0.18 ± 1.025 | -0.48 ± 1.276 | -0.09 ± 1.047 | 0.54 ± 1.162 | 1.06 ± 1.337 |
| Day 29; n= 16, 19, 17, 18, 17 | -0.31 ± 1.019 | -0.64 ± 1.332 | -0.23 ± 1.021 | 0.58 ± 1.202 | 0.40 ± 1.342 |
| Day 43; n= 16, 20, 19, 21, 20 | 0.18 ± 1.329 | -0.74 ± 1.728 | -0.50 ± 1.094 | 0.23 ± 1.410 | -0.22 ± 1.165 |
Blood samples were collected from participants to evaluate clinical hematology parameters including leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes, platelets. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| 10^12 cells/L | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Leukocytes; Day 15; n= 17, 19, 17, 21, 21 | 0.47 ± 1.271 | -0.21 ± 1.051 | 0.40 ± 1.116 | -0.03 ± 1.476 | -0.03 ± 1.463 |
| Leukocytes; Day 29; n= 16, 19, 17, 18, 17 | 0.49 ± 1.849 | 0.40 ± 1.784 | 0.00 ± 1.084 | -0.14 ± 1.701 | 0.20 ± 1.526 |
| Leukocytes; Day 43; n= 16, 20, 19, 20, 19 | 0.54 ± 1.041 | 1.08 ± 1.662 | 0.23 ± 1.101 | 0.21 ± 2.615 | 0.67 ± 1.580 |
| Neutrophils; Day 15; n= 17, 19, 17, 21, 21 | 0.391 ± 1.2323 | -0.146 ± 0.9163 | 0.280 ± 1.0681 | 0.259 ± 1.3874 | 0.344 ± 1.2469 |
| Neutrophils; Day 29; n= 16, 18, 17, 17, 15 | 0.237 ± 1.6283 | 0.469 ± 1.5717 | -0.021 ± 1.0157 | -0.009 ± 1.8718 | 0.273 ± 1.5729 |
| Neutrophils; Day 43; n= 16, 20, 19, 19, 19 | 0.423 ± 1.0535 | 0.904 ± 1.3737 | 0.112 ± 1.0449 | 0.504 ± 2.3110 | 0.691 ± 1.5221 |
| Basophils; Day 15; n= 17, 19, 17, 21, 21 | 0.005 ± 0.0302 | 0.009 ± 0.0200 | -0.002 ± 0.0210 | -0.002 ± 0.0383 | 0.007 ± 0.0102 |
| Basophils; Day 29; n= 16, 18, 17, 17, 15 | 0.013 ± 0.0510 | 0.006 ± 0.0195 | -0.004 ± 0.0187 | 0.000 ± 0.0242 | 0.012 ± 0.0328 |
| Basophils; Day 43; n= 16, 20, 19, 19, 19 | 0.006 ± 0.0268 | 0.001 ± 0.0148 | -0.004 ± 0.0203 | -0.001 ± 0.0228 | 0.007 ± 0.0192 |
| Eosinophils; Day 15; n= 17, 19, 17, 21, 21 | 0.009 ± 0.0698 | -0.017 ± 0.1313 | -0.006 ± 0.1345 | -0.006 ± 0.1183 | -0.053 ± 0.1478 |
| Eosinophils; Day 29; n= 16, 18, 17, 17, 15 | 0.020 ± 0.0859 | -0.002 ± 0.1226 | -0.006 ± 0.1129 | 0.025 ± 0.0990 | 0.007 ± 0.0880 |
| Eosinophils; Day 43; n= 16, 20, 19, 19, 19 | 0.061 ± 0.1193 | 0.030 ± 0.1439 | 0.051 ± 0.1647 | 0.021 ± 0.0984 | -0.024 ± 0.1876 |
| Lymphocytes; Day 15; n= 17, 19, 17, 21, 21 | 0.082 ± 0.4256 | -0.019 ± 0.3163 | 0.106 ± 0.4617 | -0.208 ± 0.5095 | -0.236 ± 0.4298 |
| Lymphocytes; Day 29; n= 16, 18, 17, 17, 15 | 0.194 ± 0.6605 | 0.026 ± 0.4130 | 0.019 ± 0.4421 | -0.074 ± 0.7018 | -0.154 ± 0.3058 |
| Lymphocytes; Day 43; n= 16, 20, 19, 19, 19 | 0.018 ± 0.3427 | 0.061 ± 0.3332 | 0.007 ± 0.4824 | -0.064 ± 0.4759 | -0.041 ± 0.2801 |
| Monocytes; Day 15; n= 17, 19, 17, 21, 21 | -0.005 ± 0.1518 | -0.042 ± 0.1504 | -0.016 ± 0.2285 | -0.068 ± 0.1895 | -0.037 ± 0.1460 |
| Monocytes; Day 29; n= 16, 18, 17, 17, 15 | 0.027 ± 0.1553 | 0.053 ± 0.1483 | -0.031 ± 0.2194 | 0.077 ± 0.2532 | 0.015 ± 0.1878 |
| Monocytes; Day 43; n= 16, 20, 19, 19, 19 | 0.033 ± 0.1631 | 0.065 ± 0.1629 | 0.026 ± 0.2652 | -0.021 ± 0.1855 | 0.023 ± 0.1249 |
| Platelet; Day 15; n= 17, 18, 17, 20, 21 | -14.2 ± 26.24 | -16.2 ± 27.46 | -3.2 ± 38.13 | -3.3 ± 27.78 | -10.8 ± 31.95 |
| Platelet; Day 29; n= 16, 18, 17, 17, 17 | -17.1 ± 40.58 | -12.8 ± 36.55 | -18.1 ± 29.63 | 1.3 ± 35.58 | -2.4 ± 33.65 |
| Platelet; Day 43; n= 15, 19, 19, 21, 20 | -4.9 ± 37.30 | 4.4 ± 50.34 | -10.4 ± 35.12 | -1.6 ± 30.95 | -7.1 ± 31.95 |
Single measurements of 12-lead ECG were obtained in supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT interval. Number of participants who had abnormal non clinically significant (NCS) and abnormal clinically significant (CS) ECG findings at Baseline (Week -4) and Day 29 are presented.
| Participants | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Baseline(Week -4);Abnormal; NCS;n=19,20,20,22,22 | 10 | 15 | 18 | 12 | 16 |
| Baseline(Week-4);Abnormal;CS;n=19,20,20,22,22 | 0 | 0 | 0 | 1 | 0 |
| Day 29; Abnormal; NCS; n=17,19,18,19,17 | 12 | 14 | 16 | 8 | 12 |
| Day 29; Abnormal; CS; n=17,19,18,19,17 | 0 | 0 | 0 | 1 | 0 |
Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure HR. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value.
| Beats per minute | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in ECG Mean Heart Rate | -2.0 ± 8.66 | 0.5 ± 10.53 | 1.1 ± 7.40 | 2.2 ± 7.51 | 0.9 ± 7.09 |
Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure PR interval, QRS duration, QT interval and QTcB. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Milliseconds (msec) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| PR interval; n= 17, 18, 18, 17, 16 | 7.8 ± 16.86 | 7.3 ± 12.37 | -3.3 ± 23.04 | 2.1 ± 27.13 | -11.5 ± 24.77 |
| QRS duration; n= 17, 19, 18, 19, 17 | -1.4 ± 14.05 | -5.7 ± 13.36 | -4.7 ± 47.01 | 1.7 ± 14.33 | 2.5 ± 8.97 |
| QT interval; n= 17, 19, 18, 19, 17 | 10.5 ± 27.16 | 0.7 ± 31.11 | -19.2 ± 62.37 | -1.4 ± 17.72 | -8.2 ± 33.24 |
| QTcB; n= 17, 19, 18, 19, 17 | 0.0 ± 30.84 | 5.6 ± 17.40 | -3.7 ± 44.86 | 1.1 ± 20.84 | -5.7 ± 31.65 |
Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair at specific time points. SBP and DBP were measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Millimeter of mercury (mmHg) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| SBP; pre-dialysis; Day 1; n= 19, 20, 20, 22, 22 | 142.5 ± 22.15 | 136.6 ± 15.39 | 149.2 ± 26.36 | 144.1 ± 24.27 | 144.1 ± 17.01 |
| SBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 138.8 ± 24.12 | 138.3 ± 16.14 | 139.0 ± 22.77 | 146.6 ± 20.75 | 142.3 ± 14.90 |
| SBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 143.0 ± 22.08 | 133.1 ± 18.65 | 143.1 ± 23.21 | 144.2 ± 23.27 | 148.7 ± 19.17 |
| SBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 140.0 ± 22.01 | 137.9 ± 13.21 | 142.0 ± 24.23 | 149.0 ± 23.32 | 147.1 ± 19.18 |
| DBP; pre-dialysis; Day 1; n= 19, 20, 20, 22, 22 | 71.9 ± 14.84 | 68.8 ± 11.02 | 73.3 ± 12.96 | 71.8 ± 14.38 | 72.2 ± 13.64 |
| DBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 72.5 ± 17.76 | 70.0 ± 11.92 | 70.1 ± 10.50 | 73.5 ± 13.69 | 69.7 ± 12.43 |
| DBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 70.4 ± 15.43 | 63.5 ± 13.55 | 70.9 ± 12.86 | 73.3 ± 13.17 | 72.7 ± 9.96 |
| DBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 72.5 ± 14.73 | 66.8 ± 11.94 | 69.9 ± 13.54 | 77.9 ± 16.03 | 72.8 ± 10.52 |
| SBP; post-dialysis; Day 1; n= 19, 20, 20, 22, 22 | 138.6 ± 18.57 | 137.0 ± 22.10 | 139.9 ± 22.24 | 136.7 ± 21.15 | 140.1 ± 20.10 |
| SBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 138.6 ± 21.83 | 135.5 ± 21.63 | 137.7 ± 23.02 | 137.4 ± 17.58 | 140.9 ± 15.34 |
| SBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 135.7 ± 26.04 | 130.1 ± 18.50 | 133.7 ± 23.88 | 142.8 ± 23.96 | 147.8 ± 19.09 |
| SBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 137.5 ± 22.74 | 135.8 ± 21.05 | 130.4 ± 15.47 | 145.2 ± 20.66 | 137.5 ± 22.74 |
| DBP; post-dialysis; Day 1; n= 19, 20, 20, 22, 22 | 72.1 ± 15.11 | 67.9 ± 11.49 | 68.7 ± 11.64 | 71.1 ± 12.92 | 71.5 ± 11.17 |
| DBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 72.4 ± 16.41 | 70.1 ± 12.84 | 67.8 ± 11.10 | 71.3 ± 11.07 | 71.1 ± 9.51 |
| DBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 73.9 ± 15.11 | 64.4 ± 9.83 | 67.9 ± 12.00 | 72.4 ± 12.43 | 72.9 ± 11.18 |
| DBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 69.5 ± 15.24 | 67.4 ± 10.90 | 67.4 ± 11.24 | 72.9 ± 12.60 | 75.3 ± 7.89 |
Vital sign measurements including pulse rate values were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Beats per minute | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Pre-dialysis; Day 1; n= 19, 20, 20, 22, 22 | 68.5 ± 7.95 | 69.9 ± 9.18 | 66.7 ± 7.01 | 71.4 ± 11.25 | 76.5 ± 9.35 |
| Pre-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 76.1 ± 10.31 | 67.3 ± 9.20 | 68.3 ± 7.51 | 72.1 ± 11.89 | 75.1 ± 12.68 |
| Pre-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 70.4 ± 8.31 | 70.3 ± 11.54 | 69.6 ± 9.53 | 70.8 ± 9.91 | 73.4 ± 11.45 |
| Pre-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 71.5 ± 9.17 | 69.9 ± 9.34 | 66.9 ± 6.74 | 71.3 ± 10.08 | 75.8 ± 8.29 |
| Post-dialysis; Day 1; n= 19, 20, 20, 22, 22 | 71.0 ± 11.54 | 68.7 ± 11.19 | 66.3 ± 8.37 | 73.2 ± 12.77 | 78.8 ± 11.61 |
| Post-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 72.5 ± 12.69 | 67.7 ± 12.24 | 70.1 ± 12.49 | 73.0 ± 12.07 | 78.1 ± 15.72 |
| Post-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 73.6 ± 7.10 | 69.9 ± 9.60 | 68.8 ± 11.29 | 72.2 ± 9.52 | 77.4 ± 10.04 |
| Post-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 72.0 ± 12.04 | 69.1 ± 10.21 | 68.0 ± 10.28 | 71.9 ± 11.02 | 77.3 ± 10.26 |
Vital sign measurements including weight values were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Kilograms (kg) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 1; n= 19, 20, 20, 22, 22 | 82.38 ± 25.941 | 80.04 ± 25.996 | 78.83 ± 21.331 | 79.38 ± 23.345 | 76.03 ± 16.877 |
| Day 15; n= 17, 20, 18, 22, 21 | 84.24 ± 26.652 | 80.00 ± 25.887 | 79.82 ± 22.200 | 79.44 ± 23.500 | 75.55 ± 17.595 |
| Day 29; n= 17, 19, 18, 19, 17 | 83.22 ± 27.198 | 81.04 ± 25.925 | 80.02 ± 22.286 | 82.66 ± 23.036 | 76.07 ± 18.135 |
| Day 43; n= 16, 20, 19, 21, 21 | 83.93 ± 27.589 | 80.21 ± 26.683 | 79.25 ± 21.757 | 80.64 ± 23.347 | 73.66 ± 11.614 |
Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair. SBP and DBP were measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as SBP and DBP value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| mmHg | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| SBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21 | -2.9 ± 22.03 | 1.7 ± 14.14 | -5.6 ± 14.77 | 2.5 ± 20.68 | -1.4 ± 16.35 |
| SBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17 | -0.6 ± 20.32 | -3.9 ± 19.72 | -4.7 ± 18.17 | 1.3 ± 17.51 | 4.5 ± 20.03 |
| SBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21 | -2.1 ± 21.34 | 1.2 ± 17.14 | -6.2 ± 13.83 | 3.3 ± 19.47 | 4.3 ± 10.03 |
| SBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 5.4 ± 21.39 | -3.6 ± 20.13 | 6.1 ± 20.81 | 5.7 ± 21.07 | -0.7 ± 22.33 |
| SBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 2.3 ± 19.72 | -9.4 ± 18.50 | 0.8 ± 24.79 | 9.3 ± 19.03 | 4.0 ± 19.76 |
| SBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 3.1 ± 22.22 | -3.2 ± 21.71 | -3.6 ± 17.88 | 12.0 ± 20.19 | 4.7 ± 20.11 |
| DBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 1.1 ± 10.57 | 1.2 ± 8.85 | -1.7 ± 9.78 | 1.8 ± 12.68 | -2.1 ± 11.04 |
| DBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17 | -0.3 ± 11.09 | -4.7 ± 10.04 | -3.0 ± 8.99 | 1.4 ± 10.50 | -0.1 ± 13.80 |
| DBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 2.2 ± 8.80 | -2.0 ± 9.47 | -3.1 ± 11.06 | 5.2 ± 15.08 | 2.1 ± 11.00 |
| DBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 2.4 ± 11.41 | 2.4 ± 7.71 | -2.9 ± 11.11 | 3.6 ± 9.84 | -0.8 ± 14.13 |
| DBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 3.7 ± 12.93 | -2.5 ± 8.52 | -3.2 ± 11.61 | 4.1 ± 9.33 | 0.2 ± 10.59 |
| DBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21 | -0.6 ± 10.07 | -0.3 ± 9.53 | -3.8 ± 12.13 | 4.5 ± 9.99 | 4.8 ± 10.28 |
Vital sign measurements including pulse rate were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as pulse rate value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as pulse rate value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Beats per minute | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Pre-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 7.0 ± 9.50 | -2.6 ± 8.46 | 2.3 ± 5.76 | 0.7 ± 11.46 | -1.4 ± 11.15 |
| Pre-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 2.4 ± 6.92 | 0.9 ± 12.86 | 3.4 ± 7.58 | 0.5 ± 10.01 | -3.0 ± 9.14 |
| Pre-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 3.1 ± 9.59 | 0.1 ± 6.57 | 0.8 ± 6.11 | -0.6 ± 10.03 | 0.2 ± 6.79 |
| Post-dialysis; Day 15; n= 17, 20, 18, 22, 21 | 2.2 ± 11.61 | -1.2 ± 12.86 | 1.1 ± 10.15 | 0.5 ± 8.00 | 4.4 ± 13.28 |
| Post-dialysis; Day 29; n= 17, 19, 18, 19, 17 | 4.2 ± 9.13 | 1.5 ± 13.13 | -0.8 ± 9.79 | 2.6 ± 9.04 | 6.0 ± 7.50 |
| Post-dialysis; Day 43; n= 16, 20, 19, 21, 21 | 2.3 ± 8.67 | 0.3 ± 12.96 | -0.8 ± 9.32 | -0.1 ± 9.08 | 3.9 ± 9.32 |
Vital sign measurements including weight were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| kg | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Day 15; n= 17, 20, 18, 22, 21 | -0.16 ± 0.634 | 0.16 ± 0.971 | -0.01 ± 0.617 | 0.06 ± 0.799 | -0.31 ± 1.215 |
| Day 29; n= 17, 19, 18, 19, 17 | -0.11 ± 1.053 | -0.05 ± 1.583 | -1.23 ± 5.913 | -0.16 ± 1.046 | -0.19 ± 1.244 |
| Day 43; n= 16, 20, 19, 21, 21 | -0.21 ± 0.665 | 0.37 ± 2.760 | -1.39 ± 5.759 | 0.15 ± 1.472 | 0.33 ± 2.169 |
Collected over On-therapy serious adverse events (SAEs) and non-serious adverse events (AEs) are presented from the start of study treatment to the end of the 29-day study treatment period plus 1 day, inclusive; an average of 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/19 (0%) | 2/19 (10.5%) | 5/19 (26.3%) |
| Dapro 10 mg | 0/20 (0%) | 3/20 (15%) | 8/20 (40%) |
| Dapro 15 mg | 0/20 (0%) | 2/20 (10%) | 4/20 (20%) |
| Dapro 25 mg | 0/22 (0%) | 1/22 (4.5%) | 2/22 (9.1%) |
| Dapro 30 mg | 0/22 (0%) | 2/22 (9.1%) | 0/22 (0%) |
| Event | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/19 | 2/20 | 0/20 | 0/22 | 0/22 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 1/19 | 0/20 | 0/20 | 0/22 | 0/22 |
| Orthostatic hypotensionVascular disorders | 1/19 | 0/20 | 0/20 | 0/22 | 0/22 |
| Angina unstableCardiac disorders | 0/19 | 1/20 | 0/20 | 0/22 | 1/22 |
| Mesenteric artery stenosisGastrointestinal disorders | 0/19 | 0/20 | 1/20 | 0/22 | 0/22 |
| Post procedural myocardial infarctionInjury, poisoning and procedural complications | 0/19 | 1/20 | 0/20 | 0/22 | 0/22 |
| Hypertensive crisisVascular disorders | 0/19 | 0/20 | 1/20 | 0/22 | 0/22 |
| Fluid overloadMetabolism and nutrition disorders | 0/19 | 0/20 | 0/20 | 1/22 | 1/22 |
| Event | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/19 | 2/20 | 0/20 | 0/22 | 0/22 |
| AstheniaGeneral disorders | 1/19 | 0/20 | 1/20 | 0/22 | 0/22 |
| Helicobacter gastritisInfections and infestations | 1/19 | 0/20 | 0/20 | 0/22 | 0/22 |
| DehydrationMetabolism and nutrition disorders | 1/19 | 0/20 | 0/20 | 0/22 | 0/22 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/19 | 0/20 | 0/20 | 0/22 | 0/22 |
| DizzinessNervous system disorders | 1/19 | 1/20 | 0/20 | 0/22 | 0/22 |
| HeadacheNervous system disorders | 1/19 | 0/20 | 0/20 | 0/22 | 0/22 |
| Bundle branch block leftCardiac disorders | 0/19 | 0/20 | 1/20 | 0/22 | 0/22 |
| HyperparathyroidismEndocrine disorders | 0/19 | 1/20 | 0/20 | 0/22 | 0/22 |
| DyspepsiaGastrointestinal disorders | 0/19 | 0/20 | 1/20 | 0/22 | 0/22 |
| Age, Continuous(Years) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 61.0 ± 13.06 | 63.6 ± 16.98 | 59.5 ± 12.26 | 67.2 ± 15.22 | 65.4 ± 13.97 | 63.4 ± 14.39 |
| Sex: Female, Male(Participants) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg | Total |
|---|---|---|---|---|---|---|
| Female | 11 | 8 | 6 | 9 | 8 | 42 |
| Male | 9 | 12 | 14 | 12 | 14 | 61 |
| Race/Ethnicity, Customized(Participants) | Placebo | Dapro 10 mg | Dapro 15 mg | Dapro 25 mg | Dapro 30 mg | Total |
|---|---|---|---|---|---|---|
| Race customized — African American/African Heritage | 6 | 6 | 7 | 5 | 6 | 30 |
| Race customized — American Indian Or Alaskan Native | 0 | 1 | 0 | 0 | 1 | 2 |
| Race customized — Asian - Central/South Asian Heritage | 0 | 1 | 1 | 0 | 0 | 2 |
| Race customized — Native Hawaiian Or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Race customized — White- Arabic/North African Heritage | 0 | 0 | 0 | 1 | 0 | 1 |
| Race customized — White-White/Caucasian/European Heritage | 14 | 12 | 12 | 14 | 15 | 67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Feb 2016 to primary completion in Jan 2017, 11 months.
Results were first posted in May 2018, 1 year 3 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 11 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863